WO2020118597A1 - Procédé de fabrication de 1- [ (3r, 4s) -4-cyanotétrahydropyran-3-yl] -3- [ (2-fluoro-6-méthoxy-4-pyridyl) amino] pyrazole-4-carboxamide - Google Patents

Procédé de fabrication de 1- [ (3r, 4s) -4-cyanotétrahydropyran-3-yl] -3- [ (2-fluoro-6-méthoxy-4-pyridyl) amino] pyrazole-4-carboxamide Download PDF

Info

Publication number
WO2020118597A1
WO2020118597A1 PCT/CN2018/120821 CN2018120821W WO2020118597A1 WO 2020118597 A1 WO2020118597 A1 WO 2020118597A1 CN 2018120821 W CN2018120821 W CN 2018120821W WO 2020118597 A1 WO2020118597 A1 WO 2020118597A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
alkyl
yield
reacting
Prior art date
Application number
PCT/CN2018/120821
Other languages
English (en)
Inventor
Christophe Pierre Alain Chassaing
Jingjun Yin
Edward Cleator
Lichen SONG
Wensong Xiao
Thomas Dahmen
Daniel Salanta
Claudia SCHEIPERS
Harald Schmitt
Original Assignee
Intervet International B.V.
Intervet Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International B.V., Intervet Inc. filed Critical Intervet International B.V.
Priority to PCT/CN2018/120821 priority Critical patent/WO2020118597A1/fr
Priority to PCT/EP2019/084887 priority patent/WO2020120673A1/fr
Priority to US17/311,615 priority patent/US20220017499A1/en
Priority to CA3122183A priority patent/CA3122183A1/fr
Priority to JP2021533236A priority patent/JP7497357B2/ja
Priority to BR112021011084-4A priority patent/BR112021011084A2/pt
Priority to EP19817316.3A priority patent/EP3894403A1/fr
Priority to CN201980082538.2A priority patent/CN113227077A/zh
Publication of WO2020118597A1 publication Critical patent/WO2020118597A1/fr
Priority to JP2024015683A priority patent/JP2024054201A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Definitions

  • WO 2018/108969 discloses compounds of formula I which are selective Janus kinase (JAK) inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as atopic dermatitis, arthritis, and cancer. Specifically, 1- [ (3R, 4S) -4-cyanotetrahydropyran-3-yl] -3- [ (2-fluoro-6-methoxy-4-pyridyl) amino] pyrazole-4-carboxamide (I) is disclosed.
  • WO 2013/041042 discloses pyrazole carboxamides as Janus kinase inhibitors that are useful for the treatment of rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD) and cancer.
  • the compounds of this disclosure are of the following formula.
  • R 1 is C 1 -C 4 alkyl, preferably C 1 -C 2 alkyl, most preferably ethyl with a compound of Formula (XII)
  • the borylation step is performed in the presence of 4, 4 ⁇ -di-tert-butylbipyridine or of N-benzyl-1-phenyl-N- (2-pyridylmethyleneamino) methanamine as ligands.
  • the borylation step is performed in an organic solvent such as tetrahydrofuran, cyclohexane or dioxane. Conversion of the obtained boronic ester (VIII) into the corresponding bromide (XI) is then achieved in the presence of a brominating agent.
  • the brominating agent is chosen from copper (I) bromide associated with an oxidazing agent or copper (II) bromide. In another embodiment of the invention, the brominating agent is copper (II) bromide.
  • the introduction of the 6-methoxy substituent to deliver the target 2-fluoro-4-bromo-6-methoxy-pyridine (XIIb) is achieved in the presence of an alkali methoxide such as potassium or sodium methoxide. In one embodiment of the invention, the alkali methoxide is sodium methoxide.
  • 2-Fluoro-4-iodo-6-methoxy-pyridine (XIIa) is thus obtained in high purity and yield and in a single synthetic step from 2-fluoro-6-methoxy-pyridine (IX) via a novel halogenation /halogen dance protocol.
  • the halogenation/halogen dance step is performed in the presence of a lithium amide base.
  • the lithium amide base is chosen from lithium 2, 2, 6, 6-tetramethylpiperidide and lithium diisopropylamide.
  • the lithium amide base is lithium 2, 2, 6, 6-tetramethylpiperidide.
  • the halogenation/halogen dance step is performed in the presence of 2 to 2.5 equivalent of lithium amide base.
  • the reaction is performed in the presence of 2 to 2.1 equivalent lithium amide base.
  • the halogenation/halogen dance reaction is performed at a temperature between -78 and -65 °C.
  • the reaction is performed between -75 and -70 °C.
  • the reaction is performed using 15 to 20 volumes of solvent.
  • This new intermediate (V) offers the advantages over the parent amide (XV) to be much more soluble in organic solvents and to be amenable to clean conversion into 1- [ (3R, 4S) -4-cyanotetrahydropyran-3-yl] -3- [ (2-fluoro-6-methoxy-4-pyridyl) amino] pyrazole-4-carboxamide (I) . Due to the higher solubility in organic solvents a new scalable and much more cost efficient chiral separation of the racemate (V) is achieved.
  • Ethyl 3-amino-1- [ (3R, 4S) -4-cyanotetrahydropyran-3-yl] pyrazole-4-carboxylate (VI) is prepared by the reaction of ethyl 3-amino-1H-pyrazole-4-carboxylate (IV) with 3, 6-dihydro-2H-pyran-4-carbonitrile (III) in the presence of a base in an organic solvent at elevated temperature, followed by chiral separation (scheme 6) .
  • the base is selected from 1, 8-diazabicyclo [5.4.0] undec-7-ene, potassium carbonate, potassium phosphate tribasic. In another embodiment of this invention, the base is potassium carbonate or potassium phosphate tribasic.
  • the organic solvent is ethanol, 1, 4-dioxane, N, N-dimethylformamide, toluene or acetonitrile. In a sub-aspect of this invention, the organic solvent is either toluene or acetonitrile. In an embodiment of this invention, 1 to 2.5 equivalents of 3, 6-dihydro-2H-pyran-4-carbonitrile (III) are engaged in the reaction. In another embodiment of the invention, 1.1 to 1.5 equivalents of 3, 6-dihydro-2H-pyran-4-carbonitrile (III) are engaged in the reaction
  • the palladium catalyst is chosen from tris (dibenzylideneacetone) dipalladium (0) , allylpalladium (II) chloride dimer, [ (2-di-tert-butylphosphino-3, 6-dimethoxy-2′, 4′, 6′-triisopropyl-1, 1′-biphenyl) -2- (2′-amino-1, 1′-biphenyl) ] palladium (II) methanesulfonate and palladium (II) acetate and the ligand is selected from 2- (di-tert-butylphosphino) -2′, 4′, 6′-triisopropyl-3, 6-dimethoxy-1, 1′-biphenyl, 2-di-tert-butylphosphino-2′, 4′, 6′-triisopropylbiphenyl and 4, 5-bis (diphenylphosphino)
  • the lithium salt is lithium bromide, lithium chloride or lithium hydroxide. In another embodiment of the invention, the lithium salt is either lithium bromide or lithium hydroxide. In a further embodiment of the invention, the trialkylamine base is triethylamine. In another embodiment of the invention, the hydrolysis is performed at elevated temperature. In an additional embodiment of the invention, the hydrolysis is performed at a temperature between 60 and 100 °C. In a further embodiment of the invention, the hydrolysis is performed at a temperature between 65 and 85 °C.
  • the active intermediate is an acid chloride derived from the acid of formula (XIV) and is obtained by the reaction of the acid (XIV) with a chlorinating agent such as oxalyl chloride or thionyl chloride.
  • the active intermediate results from the reaction of the acid of formula (XIV) with a coupling reagent such as a carbodiimide (DCC, DIC, EDC.
  • HCl a O- (benzotriazol-1-yl) -N, N, N’, N’-tetramethyluronium salt
  • HBTU a O- (benzotriazol-1-yl) -N, N, N’, N’-tetramethyluronium salt
  • HATU a O- (7-azabenzotriazol-1-yl) -N, N, N’, N’-tetramethyluronium salt
  • an additive such as hydroxybenzotriazole or ethyl cyano (hydroxyimino) acetate.
  • Lithium tetramethylpiperidide (CAS n° 38227-87-1) (often abbreviated LiTMP or LTMP) is a chemical compound with the molecular formula C 9 H 18 LiN. It is used as a non-nucleophilic base.
  • Trimethylsilyl cyanide (CAS n° 7677-24-9) (TMSCN) is the chemical compound with the formula (CH 3 ) 3 SiCN.
  • This volatile liquid consists of a cyanide group, that is CN, attached to a trimethylsilyl group. The molecule is used in organic synthesis as the equivalent of hydrogen cyanide.
  • COD 1, 5-Cyclooctadiene (CAS n° 1552-12-1) often abbreviated COD is a chemical compound used as a ligand in numerous metal complexes.
  • Pinacol (CAS n° 76-09-5) usually abbreviated pin is often a structural component of boron esters that are engaged in organometallic coupling processes.
  • MTBE stands for methyl tert-butyl ether (CAS n° 1634-04-4) and is used as organic solvent.
  • Dibenzylideneacetone (CAS n° 35225-79-7) often abbreviated dba is a chemical compound used as a ligand in numerous metal complexes.
  • 2-Di-tert-butylphosphino-2′, 4′, 6′-triisopropylbiphenyl (CAS n° 564483-19-8) often abbreviated t-Bu Xphos or tert-Butyl Xphos is a chemical compound used as a ligand in numerous metal complexes.
  • Xantphos is a chemical compound used as a ligand in numerous metal complexes.
  • HCl are reagents used for converting carboxylic acids into the corresponding O-acylurea intermediates which are prompt to reactions with a variety of nucleophiles.
  • O- (Benzotriazol-1-yl) -N, N, N’, N’-tetramethyluronium hexafluorophosphate (CAS n° 94790-37-1) often abbreviated HBTU
  • O- (Benzotriazol-1-yl) -N, N, N’, N’-tetramethyluronium tetrafluoroborate (CAS n° 125700-67-6) often abbreviated TBTU are reagents used for converting carboxylic acids into the corresponding 1-hydroxybenzotriazole esters which are prompt to reactions with a variety of nucleophiles.
  • O- (7-Azabenzotriazol-1-yl) -N, N, N’, N’-tetramethyluronium hexafluorophosphate (CAS n° 148893-10-1) often abbreviated HATU
  • O- (7-Azabenzotriazol-1-yl) -N, N, N’, N’-tetramethyluronium tetrafluoroborate (CAS n° 873798-09-5) are reagents used for converting carboxylic acids into the corresponding 1-hydroxyazabenzotriazole esters which are prompt to reactions with a variety of nucleophiles.
  • ammonia equivalent is a synthetic equivalent of ammonia, for example ammonium chloride.
  • a brominating agent is a reagent used to introduce bromine into the reaction, for example copper (II) bromide or copper (I) bromide associated to an oxidant.
  • An embodiment of the invention is a process for making a compound of Formula (XII) ,
  • R is I
  • the process further comprises reacting the compound of Formula (X) in the presence of a lithium amide base, preferably lithium/TMP, to yield a compound of Formula (XII) a
  • step a) the product of step a) is not isolated and purified before being carried on to step b.
  • An embodiment of the invention is a process for making a compound of Formula (XII) ,
  • R is Br
  • the process further comprises reacting the compound of Formula (VIII) with a brominating agent, preferably copper (II) bromide or copper (I) bromide associated to an oxidant, preferably copper (II) bromide, to yield a compound of Formula (XI)
  • a brominating agent preferably copper (II) bromide or copper (I) bromide associated to an oxidant, preferably copper (II) bromide
  • the process further comprises reacting the compound of Formula (XI) with an alkali methoxide, preferably sodium methoxide or potassium methoxide to yield a compound of Formula (XIIb)
  • an alkali methoxide preferably sodium methoxide or potassium methoxide
  • An embodiment of the invention is a process for making a compound of Formula (VI)
  • R 1 is C 1 -C 4 alkyl, preferably C 1 -C 2 alkyl, most preferably ethyl
  • the process further comprises reacting the compound of Formula (III) with a compound of Formula (IV) in the presence of a base such as potassium phosphate tribasic or potassium acetate
  • R 1 is C 1 -C 4 alkyl, preferably C 1 -C 2 alkyl, most preferably ethyl
  • R 1 is C 1 -C 4 alkyl, preferably C 1 -C 2 alkyl, most preferably ethyl.
  • the process further comprises separating the enantiomers of the compound of Formula (V) to give the compound of Formula (VI) .
  • the separation of enantiomers is achieved by chiral chromatography.
  • An embodiment of the invention is a compound of Formula (V)
  • R 1 is C 1 -C 4 alkyl, preferably C 1 -C 2 alkyl, most preferably ethyl.
  • An embodiment of the invention is the compound of Formula (VI)
  • R 1 is C 1 -C 4 alkyl, preferably C 1 -C 2 alkyl, most preferably ethyl.
  • An embodiment of the invention is a compound of Formula (XIII)
  • R 1 is C 1 -C 4 alkyl, preferably C 1 -C 2 alkyl, most preferably ethyl.
  • An embodiment of the invention is a compound of Formula (XIV)
  • An additional embodiment of the invention is a process to make the compound of Formula (I)
  • Eluents A: acetonitrile with 0.05 % (vol. /vol. ) formic acid.
  • ESI/MS positive and negative ions scan: 100-1000 m/z; UV at 254 and 210 nm;
  • Eluents A: acetonitrile with 0.05 % (vol. /vol. ) formic acid.
  • ESI/MS positive and negative ions scan: 100-1000 m/z;
  • Binary pump G4220A included degasser
  • Eluents A: acetonitrile with 0.05 % (vol. /vol. ) formic acid.
  • ESI/MS positive and negative ions scan: 100-1000 m/z;
  • a jacketed glass reactor (10 L) equipped with a reflux condenser, a mechanical stirred, an internal thermometer, a gas scrubber and placed under nitrogen atmosphere is charged with dry acetonitrile (2.55 L) and with dihydro-2H-pyran-4 (3H) -one (II) (365 g, 3.65 mol) .
  • the resulting mixture is stirred and the temperature is adjusted between -5 and 0 °C.
  • Zinc iodide 35 g, 0.11 mol is added to the solution while maintaining the temperature below 10 °C.
  • reaction mixture is then cooled to room temperature and is added to a solution of iron sulfate hepta hydrate (304 g, 1.09 mol) in water (7.3 L) adjusted to pH > 10 by the addition of aqueous 50%sodium hydroxide.
  • aqueous 50%sodium hydroxide aqueous 50%sodium hydroxide.
  • the resulting mixture is extracted with methyl-tert-butyl ether (3.5 L) , the organic phase is collected and the aqueous phase is diluted with water (6 L) .
  • the diluted aqueous phase is extracted with methyl-tert-butyl ether (2 ⁇ 2.5 L) .
  • the combined organic layers are washed with aqueous saturated sodium hydrogencarbonate (1.83 L) and are concentrated under reduced pressure at 40 °C. Distillation of the crude residue under reduced pressure (bp ⁇ 45 °C at 0.5 mbar) affords the desired product (III) as colorless oil (289 g, 2.6 mol) .
  • a jacketed glass reactor (5L) equipped with a reflux condenser, a mechanical stirrer, an internal thermometer and placed under nitrogen atmosphere was charged with dry acetonitrile (750 mL) , potassium phosphate tribasic monohydrate (38.3 g, 0.16 mol) and ethyl 3-amino-1H-pyrazole-4-carboxylate (IV) (500 g, 3.19 mol) .
  • the resulting mixture was heated to 80 °C and 3, 6-dihydro-2H-pyran-4-carbonitrile (III) (462 g, 4.15 mol) was quickly added via an addition funnel.
  • the addition funnel was rinsed with acetonitrile (250 mL) which was also added to the reaction mixture.
  • the reaction mixture was reacted for 6.5 h at 80 °C under vigorous stirring before heating was stopped and the reaction mixture further stirred overnight. After concentration of the reaction mixture under reduced pressure a yellow slurry was obtained.
  • the obtained material was diluted with ethyl acetate (5 L) and the resulting solution was extracted with aqueous 1 M hydrochloric acid (3 ⁇ 1.5 L) , was washed once with brine (1 L) , was filtered over a filter filled with a pad of magnesium sulfate and was concentrated under reduced pressure to afford a yellow oil.
  • the yellow oil was taken up in methanol (1.36 L) , the resulting mixture was warmed up to 40 °C under stirring to ensure homogenization.
  • the resulting mixture was heated to 65 °C and stirred at this temperature for 90 min. After cooling to room temperature, the mixture was concentrated under reduced pressure at 40 °C.
  • the obtained crude residue was stirred with acetonitrile (650 mL) for 30 min at 50 °C. The hot solution was filtered over a pad of Celite and the filtrate was concentrated under reduced pressure. The obtained residue was taken up in 2-propanol (750 mL) , the resulting mixture was warmed to 100 °C and was then allowed to slowly reach room temperature under gentle stirring.
  • the formed precipitate was filtered off, the wet cake was rinsed with 2-propanol (50 mL) and was then dried under reduced pressure at 40 °C to afford the desired product (XIII) (61.2 g, 149 mmol) .
  • the new formed solid was washed with 2-propanol (2 ⁇ 50 mL) and was dried under reduced pressure at 40 °C to afford a second crop of desired product (XIII) (8.2 g, 19.5 mmol) .
  • the resulting mixture was heated to 60 °C and stirred at this temperature for 18 h. After cooling to room temperature, the mixture was concentrated under reduced pressure. The obtained residue was diluted with 2-propanol (20 mL) and the resulting mixture was warmed up until a solution was obtained. Heating was stopped and the solution was allowed to slowly reach room temperature. The suspension was filtered to collect the formed precipitate. The wet cake is rinsed with 2-propanol (25 mL) and was dried under reduced pressure at 40 °C to afford the desired product (XIII) as off-white solid (1.07 g, 2.75 mmol) .
  • Lithium bromide (769 mg, 8.86 mmol) and triethylamine (380 ⁇ L, 2.66 mmol) were added to a solution of ethyl 1- [ (3R, 4S) -4-cyanotetrahydropyran-3-yl] -3- [ (2-fluoro-6-methoxy-4-pyridyl) amino] pyrazole-4-carboxylate (XIII) (345 mg, 0.89 mmol) in acetonitrile (4.34 mL) and water (87 ⁇ L) and the resulting mixture was stirred at 80 °C for 20 h.
  • the reaction mixture was cooled to room temperature, was diluted with ethyl acetate (25 mL) and was extracted with aqueous saturated sodium hydrogencarbonate (3 ⁇ 10 mL) .
  • the combined aqueous layers were the acidified to pH 3 by the addition of 1 M aqueous hydrochloric acid.
  • the precipitate formed was isolated by filtration and was dried under reduced pressure at 40 °C to deliver the desired product (XIV) as colorless solid (308 mg, 0.85 mmol) .
  • N- (3-Dimethylaminopropyl) -N′-ethylcarbodiimide hydrochloride (245 mg, 1.28 mmol) , 1-hydroxybenzotriazole hydrate (131 mg, 0.85 mmol) , ammonium chloride (91 mg, 1.71 mmol) , triethylamine (238 ⁇ L, 1.71 mmol) and 1- [ (3R, 4S) -4-cyanotetrahydropyran-3-yl] -3- [ (2-fluoro-6-methoxy-4-pyridyl) amino] pyrazole-4-carboxylic acid (XIV) (308 mg, 0.85 mmol) were stirred at room temperature in a mixture of tetrahydrofuran (3 mL) and of N, N-dimethylformamide (1 mL) for 90 min.
  • a 160 L glass-lined vessel was charged with crude (I) (3.72 kg, 10.32 mol) and methanol (80.8 L) .
  • the contents were heated to reflux (65°C) and authentic crystal seeds of compound (I) (109 g, 302.5 mmol) charged as a slurry in methanol (1.9 L) .
  • the mixture was stirred at 275 rpm and aged for 14.5 h.
  • the slurry was cooled to 60°C and sampled for analysis purpose: Pure compound (I) was obtained.
  • the slurry was cooled from 65°C to 20°C over 12 h and then aged at 20°C for 6 h.
  • the batch was filtered and the cake was washed with methanol (5.4 L) .
  • N-dimethylacetamide (7.55 L) was degassed using subsurface nitrogen for 30 min.
  • tBuBrettPhos (96.0 g, 0.198 mol)
  • allyl palladium (II) chloride dimer (36.2 g, 0.099 moles) were added and the resulting mixture was stirred at 20 °C for 100 min with a subsurface nitrogen purge.
  • Another vessel was charged with compound (XVI) (2.32 kg, 9.88 mol) , with compound (XIIa) (2.50 kg, 9.88 mol) , potassium phosphate tribasic (4.19 kg, 19.76 mol) and with N, N-dimethylacetamide (17.55 L) .
  • the resulting mixture was stirred and degassed and the solution of the catalyst prepared in the first vessel was added.
  • the first vessel was rinsed with N, N-dimethylacetamide (0.5 L) which was also added to the reaction mixture.
  • the reaction mixture was then stirred at room temperature and was monitored by UV-HPLC until full conversion was observed.
  • the reaction mixture was filtered and the wet cake was washed with N, N-dimethylacetamide (5 L) .
  • the filtrate was cooled between 0 and 5 °C and water (90 L) was added over 105 min while maintaining the temperature between 0 and 5 °C.
  • the resulting slurry was aged 1 h at this temperature.
  • the slurry was then filtered and the cake was washed twice with water (10 and 20 L) and four times with methanol (15 and 3 ⁇ 19 L) .
  • the wet cake was dried under a nitrogen stream to deliver the desired compound (I) (3.14 kg, 0.154 mol) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux procédés pour la préparation de 1-[(3R,4S)-4-cyanotétrahydropyran-3-yl]-3-[(2-fluoro-6-méthoxy-4-pyridyl) amino] pyrazole-4-carboxamide (I) qui comprennent (i) une nouvelle synthèse plus efficace pour des intermédiaires bromo et iodo pyridine, (ii) la synthèse d'un nouvel intermédiaire d'ester de pyrazole qui peut être obtenu sous une forme énantiopure et (iii) la combinaison de ces intermédiaires en composé (I).
PCT/CN2018/120821 2018-12-13 2018-12-13 Procédé de fabrication de 1- [ (3r, 4s) -4-cyanotétrahydropyran-3-yl] -3- [ (2-fluoro-6-méthoxy-4-pyridyl) amino] pyrazole-4-carboxamide WO2020118597A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
PCT/CN2018/120821 WO2020118597A1 (fr) 2018-12-13 2018-12-13 Procédé de fabrication de 1- [ (3r, 4s) -4-cyanotétrahydropyran-3-yl] -3- [ (2-fluoro-6-méthoxy-4-pyridyl) amino] pyrazole-4-carboxamide
PCT/EP2019/084887 WO2020120673A1 (fr) 2018-12-13 2019-12-12 Procédé de préparation de 1-[(3r,4s)-4-cyanotétrahydropyran-3-yl]-3-[(2-fluoro-6-méthoxy-4-pyridyl)amino]pyrazole-4-carboxamide
US17/311,615 US20220017499A1 (en) 2018-12-13 2019-12-12 Process for Preparing 1-([3R,4S)-4-Cyanotetrahydropyran-3-YL]-3-[(2-fluoro-6-Methoxy-4-Pyridyl)Amino]Pyrazole-4-Carboxamide
CA3122183A CA3122183A1 (fr) 2018-12-13 2019-12-12 Procede de preparation de 1-[(3r,4s)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamide
JP2021533236A JP7497357B2 (ja) 2018-12-13 2019-12-12 １－［（３ｒ，４ｓ）－４－シアノテトラヒドロピラン－３－イル］－３－［（２－フルオロ－６－メトキシ－４－ピリジル）アミノ］ピラゾール－４－カルボキサミドの調製方法
BR112021011084-4A BR112021011084A2 (pt) 2018-12-13 2019-12-12 Processo para preparar 1-[(3r,4s)-4-cianotetrahidropiran-3-il]-3-[(2-fluoro-6-metoxi-4-piridil)amino]pirazol-4-carboxamida
EP19817316.3A EP3894403A1 (fr) 2018-12-13 2019-12-12 Procédé de préparation de 1-[(3r,4s)-4-cyanotétrahydropyran-3-yl]-3-[(2-fluoro-6-méthoxy-4-pyridyl)amino]pyrazole-4-carboxamide
CN201980082538.2A CN113227077A (zh) 2018-12-13 2019-12-12 一种制备1-[(3r,4s)-4-氰基四氢吡喃-3-基]-3-[(2-氟-6-甲氧基-4-吡啶基)氨基]吡唑-4-甲酰胺的方法
JP2024015683A JP2024054201A (ja) 2018-12-13 2024-02-05 １－［（３ｒ，４ｓ）－４－シアノテトラヒドロピラン－３－イル］－３－［（２－フルオロ－６－メトキシ－４－ピリジル）アミノ］ピラゾール－４－カルボキサミドの調製方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/120821 WO2020118597A1 (fr) 2018-12-13 2018-12-13 Procédé de fabrication de 1- [ (3r, 4s) -4-cyanotétrahydropyran-3-yl] -3- [ (2-fluoro-6-méthoxy-4-pyridyl) amino] pyrazole-4-carboxamide

Publications (1)

Publication Number Publication Date
WO2020118597A1 true WO2020118597A1 (fr) 2020-06-18

Family

ID=71075865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/120821 WO2020118597A1 (fr) 2018-12-13 2018-12-13 Procédé de fabrication de 1- [ (3r, 4s) -4-cyanotétrahydropyran-3-yl] -3- [ (2-fluoro-6-méthoxy-4-pyridyl) amino] pyrazole-4-carboxamide

Country Status (1)

Country Link
WO (1) WO2020118597A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133420A1 (fr) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Composés pyrazole contenant du bore, compositions comprenant ceux-ci, méthodes et utilisations associées
CN117049935A (zh) * 2023-10-13 2023-11-14 成都泰和伟业生物科技有限公司 一种亲电交叉偶联反应构建碳碳键的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040863A1 (fr) * 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides en tant qu'inhibiteurs de janus kinase
WO2016184652A1 (fr) * 2015-04-28 2016-11-24 Ludwig-Maximilians-Universität München Procédés de préparation de composés organiques métallés
WO2018108969A1 (fr) * 2016-12-14 2018-06-21 Intervet International B.V. Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013040863A1 (fr) * 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Cycloalkylnitrile pyrazole carboxamides en tant qu'inhibiteurs de janus kinase
WO2016184652A1 (fr) * 2015-04-28 2016-11-24 Ludwig-Maximilians-Universität München Procédés de préparation de composés organiques métallés
WO2018108969A1 (fr) * 2016-12-14 2018-06-21 Intervet International B.V. Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SADLER， SCOTT A. ET AL.: "Iridium-catalyzed C-H borylation of pyridines", ORG. BIOMOL. CHEM, vol. 12, no. 37, 1 August 2014 (2014-08-01), pages 7318, XP055711937, DOI: 20190902174303Y *
TAYLOR， NICHOLAS J. ET AL.: "Derisking the Cu-Mediated 18F-Fluorination of Heterocyclic Positron Emission Tomography Radioligands", J. AM. CHEM. SOC., vol. 139, no. 24, 12 June 2017 (2017-06-12), pages 8267 - 8276, XP055711935 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022133420A1 (fr) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Composés pyrazole contenant du bore, compositions comprenant ceux-ci, méthodes et utilisations associées
US11827657B2 (en) 2020-12-18 2023-11-28 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
CN117049935A (zh) * 2023-10-13 2023-11-14 成都泰和伟业生物科技有限公司 一种亲电交叉偶联反应构建碳碳键的方法
CN117049935B (zh) * 2023-10-13 2023-12-08 成都泰和伟业生物科技有限公司 一种亲电交叉偶联反应构建碳碳键的方法

Similar Documents

Publication Publication Date Title
CN107176955B (zh) 一种巴瑞替尼的制备方法
JP6438551B2 (ja) 置換アントラニル酸誘導体を製造する方法
JP2024054201A (ja) １－［（３ｒ，４ｓ）－４－シアノテトラヒドロピラン－３－イル］－３－［（２－フルオロ－６－メトキシ－４－ピリジル）アミノ］ピラゾール－４－カルボキサミドの調製方法
WO2020118597A1 (fr) Procédé de fabrication de 1- [ (3r, 4s) -4-cyanotétrahydropyran-3-yl] -3- [ (2-fluoro-6-méthoxy-4-pyridyl) amino] pyrazole-4-carboxamide
CN102367260A (zh) 2-氨基嘧啶-5-硼酸的合成方法
CN107628999B (zh) 阿立哌唑十二烷酸酯的制备方法
JP2007230963A (ja) ２，４−ジ置換ピリジンの製造法
WO2022082329A1 (fr) Procédés de préparation de 3-fluoro-5-(((1s, 2ar)-1, 3, 3, 4, 4-pentafluoro-2a-hydroxy-2, 2a, 3, 4-tétrahydro-1 h-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile
JP7227925B2 (ja) １－［５－（２－フルオロフェニル）－１－（ピリジン－３－イルスルホニル）－１ｈ－ピロ－ル－３－イル］－ｎ－メチルメタンアミンモノフマル酸塩の製造法
CN105622380B (zh) 一种阿普斯特的制备方法及其中间体
KR102635225B1 (ko) 4환성 화합물의 제조방법
EP4306514A1 (fr) Procédé de préparation d'intermédiaire pour la synthèse d'un agoniste du récepteur de la sphingosine-1-phosphate
CN114573512A (zh) 一种合成c2-二氟烷基苯并咪唑衍生物的方法
CN114213424A (zh) 一种呋喃[3，2-b]并吡啶衍生物的合成方法
JP4879907B2 (ja) フェニル２−ピリミジニルケトン類の製造方法及びその新規中間体
CN108250008B (zh) 3,3,3’,3’-四甲基-1,1’-螺二氢茚-6,6’-二醇衍生物手性拆分方法
CN109134306B (zh) 一种烷基酮酰胺和其肟酰胺类化合物及其制备与应用
CN106831522B (zh) 内酰胺类化合物及其制备方法
JP2014532058A (ja) ５−［２−［７−（トリフルオロメチル）−５−［４−（トリフルオロメチル）フェニル］ピラゾロ［１，５−ａ］ピリミジン−３−イル］エチニル］−２−ピリジンアミンの製造方法
CN108503583B (zh) 一种含氮氢类化合物的烷基化方法及其应用
CN111233739B (zh) 一种制备4-(2’-吲哚基)-1,3-烯炔衍生物的方法
JP5205971B2 (ja) テトラヒドロピラン化合物の製造方法
CN106366069A (zh) 一种n‑杂芳基咔唑类化合物的制备方法
TW200410930A (en) Method for producing acetylene compound
JP2022517411A (ja) テトラヒドロピリドピリミジン類の調製方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18942828

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18942828

Country of ref document: EP

Kind code of ref document: A1